AtriCure, Inc. ATRC
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ATRC
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
AtriCure, Inc. is a U.S.-based medical device company focused on the treatment of atrial fibrillation (Afib) and related cardiac conditions through surgical ablation technologies, left atrial appendage management products, and pain management solutions. The company operates within the broader cardiovascular medical technology industry and primarily serves hospitals, cardiac surgeons, electrophysiologists, and healthcare systems. Its core revenue drivers include products used in open-heart surgeries, minimally invasive cardiac procedures, and post-operative pain management. AtriCure’s portfolio is centered on enabling physicians to treat Afib during concomitant cardiac surgery and standalone procedures, with a significant emphasis on clinical evidence and physician training.
The company was founded in 2000 and is headquartered in Mason, Ohio. AtriCure developed its market position through specialized cardiac ablation technologies and expanded into adjacent cardiovascular therapies through internal product development and acquisitions. Over time, the company broadened its offerings beyond ablation devices to include left atrial appendage exclusion systems and cryo-based nerve block technologies. AtriCure’s strategic positioning is supported by its focused specialization in Afib treatment, a substantial clinical evidence base, proprietary surgical technologies, and long-standing relationships with cardiac surgery programs globally.
Business Operations
AtriCure organizes its operations around several primary product categories, including the Open Ablation platform, MIS Ablation products for minimally invasive procedures, Appendage Management solutions, and Pain Management technologies. The company generates revenue through direct sales of disposable surgical devices, capital equipment, and related accessories used in cardiovascular procedures. Its technologies include radiofrequency and cryoablation systems designed to create lesions that disrupt abnormal electrical pathways in the heart, as well as left atrial appendage exclusion devices intended to reduce stroke risk in Afib patients.
The company operates primarily in the United States while maintaining international commercial operations across Europe, Asia-Pacific, and other global markets through direct sales teams and distribution arrangements. AtriCure controls proprietary intellectual property associated with its ablation and appendage management systems and continues to invest in physician education and clinical trial infrastructure. Key subsidiaries and operational entities include AtriCure Europe B.V. and other regional commercial organizations supporting international expansion. The company has also collaborated with healthcare institutions and clinical research organizations to support evidence generation and adoption of hybrid and minimally invasive Afib treatment approaches.
Strategic Position & Investments
AtriCure’s strategic direction centers on expanding procedural adoption of surgical and hybrid Afib therapies, increasing utilization of left atrial appendage management products, and broadening the application of its cryo-based pain management technologies. The company has invested significantly in clinical trials, physician training programs, and product innovation to strengthen its position within cardiac surgery and electrophysiology markets. Its growth strategy includes increasing penetration in minimally invasive procedures and expanding indications supported by long-term clinical data.
The company has completed acquisitions and technology investments intended to strengthen its cardiovascular portfolio and support adjacent growth opportunities. AtriCure has also invested in research related to hybrid convergent procedures that combine surgical and catheter-based approaches for persistent Afib treatment. Emerging areas of focus include enhanced electrophysiology integration, expanded pain management applications, and advanced imaging or procedural guidance technologies associated with cardiac interventions. Public filings and investor materials indicate continued emphasis on international expansion and evidence-based commercialization strategies.
Geographic Footprint
AtriCure is headquartered in Mason, Ohio, United States, and maintains a commercial presence across multiple international markets. The company derives the majority of its revenue from the United States, though it has established growing operations in Europe, Asia-Pacific, and selected markets in Latin America and the Middle East through direct sales infrastructure and distributor partnerships. Its products are used in cardiac surgery centers and hospitals globally, particularly in developed healthcare systems with advanced cardiovascular treatment capabilities.
The company’s international footprint has expanded through regional subsidiaries, physician training initiatives, and participation in multinational clinical studies. AtriCure’s products have received regulatory clearances and approvals in several jurisdictions, enabling broader adoption of its ablation and appendage management technologies. Its operational influence is strongest in regions with high procedural volumes in cardiac surgery and electrophysiology, including the United States, Germany, United Kingdom, and parts of Asia-Pacific.
Leadership & Governance
AtriCure’s leadership team combines experience in medical devices, cardiovascular care, commercialization, and healthcare operations. The company was co-founded by executives and entrepreneurs focused on developing surgical solutions for Afib treatment. Corporate governance oversight is provided through a board of directors and executive leadership structure aligned with public company standards and regulatory compliance requirements disclosed in SEC filings and annual reports.
Key executives include:
- Michael H. Carrel – President and Chief Executive Officer
- M. Andreas Kolenberg – Chief Financial Officer
- Justin J. Noznesky – Chief Operating Officer
- Jamie M. Sampson – Chief Marketing Officer
- Vincent P. Burgess – Chief Medical Officer
The leadership strategy has emphasized disciplined innovation, physician-focused commercialization, clinical evidence generation, and expansion into adjacent cardiovascular therapies. Company communications and investor presentations consistently highlight long-term growth through procedural adoption, product differentiation, and global market expansion.